|
Gene: GSTP1 |
Gene summary for GSTP1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | GSTP1 | Gene ID | 2950 |
Gene name | glutathione S-transferase pi 1 | |
Gene Alias | DFN7 | |
Cytomap | 11q13.2 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | P09211 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2950 | GSTP1 | GSM4909281 | Human | Breast | IDC | 1.62e-32 | 5.06e-01 | 0.21 |
2950 | GSTP1 | GSM4909282 | Human | Breast | IDC | 2.65e-55 | 6.42e-01 | -0.0288 |
2950 | GSTP1 | GSM4909285 | Human | Breast | IDC | 1.89e-53 | 5.83e-01 | 0.21 |
2950 | GSTP1 | GSM4909287 | Human | Breast | IDC | 6.52e-30 | 4.24e-01 | 0.2057 |
2950 | GSTP1 | GSM4909288 | Human | Breast | IDC | 1.41e-09 | 3.93e-01 | 0.0988 |
2950 | GSTP1 | GSM4909290 | Human | Breast | IDC | 3.42e-03 | 2.44e-01 | 0.2096 |
2950 | GSTP1 | GSM4909291 | Human | Breast | IDC | 3.51e-39 | -1.09e+00 | 0.1753 |
2950 | GSTP1 | GSM4909292 | Human | Breast | IDC | 1.60e-02 | -6.92e-01 | 0.1236 |
2950 | GSTP1 | GSM4909293 | Human | Breast | IDC | 2.36e-08 | -3.83e-01 | 0.1581 |
2950 | GSTP1 | GSM4909294 | Human | Breast | IDC | 1.08e-50 | 5.18e-01 | 0.2022 |
2950 | GSTP1 | GSM4909295 | Human | Breast | IDC | 1.04e-08 | 3.58e-01 | 0.0898 |
2950 | GSTP1 | GSM4909296 | Human | Breast | IDC | 8.27e-17 | -8.99e-02 | 0.1524 |
2950 | GSTP1 | GSM4909297 | Human | Breast | IDC | 3.13e-68 | -1.03e+00 | 0.1517 |
2950 | GSTP1 | GSM4909298 | Human | Breast | IDC | 4.24e-56 | -9.79e-01 | 0.1551 |
2950 | GSTP1 | GSM4909301 | Human | Breast | IDC | 4.62e-68 | -1.08e+00 | 0.1577 |
2950 | GSTP1 | GSM4909302 | Human | Breast | IDC | 9.55e-25 | -7.40e-01 | 0.1545 |
2950 | GSTP1 | GSM4909304 | Human | Breast | IDC | 1.83e-77 | -1.13e+00 | 0.1636 |
2950 | GSTP1 | GSM4909306 | Human | Breast | IDC | 9.75e-17 | -5.54e-01 | 0.1564 |
2950 | GSTP1 | GSM4909307 | Human | Breast | IDC | 3.44e-41 | -7.81e-01 | 0.1569 |
2950 | GSTP1 | GSM4909308 | Human | Breast | IDC | 1.29e-60 | -1.12e+00 | 0.158 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:20012339 | Breast | Precancer | regulation of apoptotic signaling pathway | 65/1080 | 356/18723 | 7.70e-17 | 3.17e-14 | 65 |
GO:00069799 | Breast | Precancer | response to oxidative stress | 70/1080 | 446/18723 | 1.59e-14 | 4.26e-12 | 70 |
GO:00485459 | Breast | Precancer | response to steroid hormone | 53/1080 | 339/18723 | 3.07e-11 | 3.66e-09 | 53 |
GO:20012349 | Breast | Precancer | negative regulation of apoptotic signaling pathway | 39/1080 | 224/18723 | 5.35e-10 | 4.77e-08 | 39 |
GO:00003029 | Breast | Precancer | response to reactive oxygen species | 38/1080 | 222/18723 | 1.47e-09 | 1.23e-07 | 38 |
GO:00319608 | Breast | Precancer | response to corticosteroid | 30/1080 | 167/18723 | 2.50e-08 | 1.65e-06 | 30 |
GO:00513848 | Breast | Precancer | response to glucocorticoid | 26/1080 | 148/18723 | 3.32e-07 | 1.57e-05 | 26 |
GO:00603266 | Breast | Precancer | cell chemotaxis | 41/1080 | 310/18723 | 5.99e-07 | 2.55e-05 | 41 |
GO:00988698 | Breast | Precancer | cellular oxidant detoxification | 20/1080 | 101/18723 | 1.07e-06 | 4.18e-05 | 20 |
GO:19907488 | Breast | Precancer | cellular detoxification | 21/1080 | 116/18723 | 2.67e-06 | 8.89e-05 | 21 |
GO:20012369 | Breast | Precancer | regulation of extrinsic apoptotic signaling pathway | 24/1080 | 151/18723 | 5.78e-06 | 1.70e-04 | 24 |
GO:00022378 | Breast | Precancer | response to molecule of bacterial origin | 43/1080 | 363/18723 | 6.05e-06 | 1.72e-04 | 43 |
GO:00987548 | Breast | Precancer | detoxification | 24/1080 | 152/18723 | 6.49e-06 | 1.81e-04 | 24 |
GO:00324968 | Breast | Precancer | response to lipopolysaccharide | 41/1080 | 343/18723 | 7.94e-06 | 2.17e-04 | 41 |
GO:00972378 | Breast | Precancer | cellular response to toxic substance | 21/1080 | 124/18723 | 7.98e-06 | 2.17e-04 | 21 |
GO:00971919 | Breast | Precancer | extrinsic apoptotic signaling pathway | 30/1080 | 219/18723 | 9.42e-06 | 2.50e-04 | 30 |
GO:0050727 | Breast | Precancer | regulation of inflammatory response | 44/1080 | 386/18723 | 1.26e-05 | 3.22e-04 | 44 |
GO:00713838 | Breast | Precancer | cellular response to steroid hormone stimulus | 28/1080 | 204/18723 | 1.78e-05 | 4.26e-04 | 28 |
GO:00342849 | Breast | Precancer | response to monosaccharide | 29/1080 | 225/18723 | 4.19e-05 | 9.00e-04 | 29 |
GO:00725938 | Breast | Precancer | reactive oxygen species metabolic process | 30/1080 | 239/18723 | 5.13e-05 | 1.07e-03 | 30 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0541823 | Lung | AIS | Fluid shear stress and atherosclerosis | 33/961 | 139/8465 | 2.48e-05 | 4.73e-04 | 3.03e-04 | 33 |
hsa0521521 | Lung | AIS | Prostate cancer | 24/961 | 97/8465 | 1.57e-04 | 1.82e-03 | 1.16e-03 | 24 |
hsa0522521 | Lung | AIS | Hepatocellular carcinoma | 31/961 | 168/8465 | 4.11e-03 | 2.15e-02 | 1.38e-02 | 31 |
hsa0541833 | Lung | AIS | Fluid shear stress and atherosclerosis | 33/961 | 139/8465 | 2.48e-05 | 4.73e-04 | 3.03e-04 | 33 |
hsa0521531 | Lung | AIS | Prostate cancer | 24/961 | 97/8465 | 1.57e-04 | 1.82e-03 | 1.16e-03 | 24 |
hsa0522531 | Lung | AIS | Hepatocellular carcinoma | 31/961 | 168/8465 | 4.11e-03 | 2.15e-02 | 1.38e-02 | 31 |
hsa0541843 | Lung | MIAC | Fluid shear stress and atherosclerosis | 19/507 | 139/8465 | 5.95e-04 | 7.61e-03 | 5.51e-03 | 19 |
hsa0521541 | Lung | MIAC | Prostate cancer | 15/507 | 97/8465 | 6.02e-04 | 7.61e-03 | 5.51e-03 | 15 |
hsa0522541 | Lung | MIAC | Hepatocellular carcinoma | 20/507 | 168/8465 | 2.44e-03 | 2.16e-02 | 1.56e-02 | 20 |
hsa0541853 | Lung | MIAC | Fluid shear stress and atherosclerosis | 19/507 | 139/8465 | 5.95e-04 | 7.61e-03 | 5.51e-03 | 19 |
hsa0521551 | Lung | MIAC | Prostate cancer | 15/507 | 97/8465 | 6.02e-04 | 7.61e-03 | 5.51e-03 | 15 |
hsa0522551 | Lung | MIAC | Hepatocellular carcinoma | 20/507 | 168/8465 | 2.44e-03 | 2.16e-02 | 1.56e-02 | 20 |
hsa0541830 | Oral cavity | OSCC | Fluid shear stress and atherosclerosis | 92/3704 | 139/8465 | 6.51e-08 | 4.84e-07 | 2.47e-07 | 92 |
hsa0521510 | Oral cavity | OSCC | Prostate cancer | 66/3704 | 97/8465 | 1.05e-06 | 5.89e-06 | 3.00e-06 | 66 |
hsa015246 | Oral cavity | OSCC | Platinum drug resistance | 51/3704 | 73/8465 | 5.41e-06 | 2.75e-05 | 1.40e-05 | 51 |
hsa0522516 | Oral cavity | OSCC | Hepatocellular carcinoma | 97/3704 | 168/8465 | 1.63e-04 | 5.52e-04 | 2.81e-04 | 97 |
hsa0048016 | Oral cavity | OSCC | Glutathione metabolism | 36/3704 | 57/8465 | 2.41e-03 | 6.41e-03 | 3.26e-03 | 36 |
hsa05418114 | Oral cavity | OSCC | Fluid shear stress and atherosclerosis | 92/3704 | 139/8465 | 6.51e-08 | 4.84e-07 | 2.47e-07 | 92 |
hsa0521515 | Oral cavity | OSCC | Prostate cancer | 66/3704 | 97/8465 | 1.05e-06 | 5.89e-06 | 3.00e-06 | 66 |
hsa0152413 | Oral cavity | OSCC | Platinum drug resistance | 51/3704 | 73/8465 | 5.41e-06 | 2.75e-05 | 1.40e-05 | 51 |
Page: 1 2 3 4 5 6 7 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GSTP1 | SNV | Missense_Mutation | c.203N>G | p.Thr68Ser | p.T68S | P09211 | protein_coding | tolerated(0.13) | benign(0.007) | TCGA-D8-A27M-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | methotrexate+5 | SD | |
GSTP1 | SNV | Missense_Mutation | novel | c.414G>C | p.Gln138His | p.Q138H | P09211 | protein_coding | tolerated(0.28) | benign(0.003) | TCGA-Q1-A73Q-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
GSTP1 | SNV | Missense_Mutation | c.500C>A | p.Ala167Asp | p.A167D | P09211 | protein_coding | tolerated(0.07) | possibly_damaging(0.793) | TCGA-AA-3697-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
GSTP1 | SNV | Missense_Mutation | rs188653023 | c.548G>A | p.Arg183His | p.R183H | P09211 | protein_coding | deleterious(0.04) | benign(0.087) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
GSTP1 | SNV | Missense_Mutation | c.601N>G | p.Asn201Asp | p.N201D | P09211 | protein_coding | tolerated(0.2) | benign(0.007) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
GSTP1 | SNV | Missense_Mutation | c.533C>T | p.Ser178Leu | p.S178L | P09211 | protein_coding | tolerated(0.11) | benign(0.049) | TCGA-AP-A0LF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
GSTP1 | SNV | Missense_Mutation | rs752233998 | c.547N>T | p.Arg183Cys | p.R183C | P09211 | protein_coding | tolerated(0.05) | benign(0.177) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
GSTP1 | SNV | Missense_Mutation | novel | c.91N>A | p.Glu31Lys | p.E31K | P09211 | protein_coding | deleterious(0.02) | probably_damaging(0.964) | TCGA-DF-A2KN-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
GSTP1 | SNV | Missense_Mutation | c.148N>C | p.Tyr50His | p.Y50H | P09211 | protein_coding | deleterious(0) | possibly_damaging(0.903) | TCGA-BC-A3KF-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
GSTP1 | SNV | Missense_Mutation | rs752731774 | c.212N>A | p.Arg71His | p.R71H | P09211 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-DD-A4ND-01 | Liver | liver hepatocellular carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2950 | GSTP1 | ENZYME, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | DNR | 10050715 | ||
2950 | GSTP1 | ENZYME, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | FOLFOX REGIMEN | 19922504 | ||
2950 | GSTP1 | ENZYME, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | NITROGEN MUSTARD | 2882834 | ||
2950 | GSTP1 | ENZYME, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | ADM | 9382956 | ||
2950 | GSTP1 | ENZYME, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | thiotepa | THIOTEPA | ||
2950 | GSTP1 | ENZYME, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | PREDNISONE | PREDNISONE | 11186134 | |
2950 | GSTP1 | ENZYME, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | CARBOPLATIN | CARBOPLATIN | 12360105 | |
2950 | GSTP1 | ENZYME, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | epirubicin | EPIRUBICIN | 25008867,21362365,20568049 | |
2950 | GSTP1 | ENZYME, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | 5-AZACYTIDINE | AZACITIDINE | 11696442 | |
2950 | GSTP1 | ENZYME, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | fluorouracil | FLUOROURACIL | 27995989,21449681,18540691 |
Page: 1 2 3 4 5 6 7 8 |